EGFR and neoplasm: The observation of significant clinical response despite the presence of a KRAS mutation with oncogenic biochemical features [2] was counterintuitive and led us to postulate that the mechanistic impact of this missense variant may in fact be distinct from other common KRAS mutations and permit tumor response to EGFR inhibition.